2022 World Conference on Lung Cancer (ePosters)-EP08.02-138. SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

EP08.02-138. SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

Back to course

Pdf Summary

The SAFFRON study aims to investigate the efficacy and safety of the combination of savolitinib and osimertinib compared to platinum-based chemotherapy in patients with EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have progressed on osimertinib treatment due to increased levels of MET protein and/or MET gene in the tumor. Osimertinib is an EGFR-tyrosine kinase inhibitor (TKI) that is commonly used as a first-line treatment for EGFRm NSCLC. However, patients may develop resistance to osimertinib, often due to increased MET levels. The combination of savolitinib and osimertinib has shown preliminary evidence of activity in patients with MET-amplified NSCLC in previous studies.<br /><br />The SAFFRON study is a global, multicenter, randomized, open-label Phase III study that plans to enroll approximately 324 patients from 27 countries. The primary endpoints of the study include overall survival, objective response rate, duration of response, disease control rate, time to discontinuation of treatment or death, tumor shrinkage, time to deterioration in pulmonary core symptoms, and pharmacokinetics. The study will assess these endpoints in patients receiving the combination of savolitinib and osimertinib compared to those receiving platinum-based chemotherapy.<br /><br />The study will also evaluate progression-free survival, disease-relevant markers in tumor specimens and blood samples, and safety parameters such as adverse events, discontinuation due to adverse events, and clinical chemistry and hematology. Tumor assessments will be performed using computed tomography or magnetic resonance imaging.<br /><br />The SAFFRON study is expected to provide valuable insights into the efficacy and safety of the combination of savolitinib and osimertinib in patients with EGFRm NSCLC who have developed resistance to osimertinib due to increased MET levels. The results of this study are anticipated to be available in July 2025.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

SAFFRON study

efficacy

safety

savolitinib

osimertinib

platinum-based chemotherapy

EGFR-mutated non-small cell lung cancer

MET protein

MET gene

osimertinib resistance